Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction.
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
19
06
2019
revised:
07
10
2019
accepted:
21
10
2019
pubmed:
12
11
2019
medline:
22
6
2021
entrez:
12
11
2019
Statut:
ppublish
Résumé
Pulmonary hypertension (PH) is a progressive pulmonary vasculopathy that causes chronic right ventricular pressure overload and often leads to right ventricular failure. Various kinase inhibitors have been studied in the setting of PH and either improved or worsened the disease, highlighting the importance of understanding the specific role of the respective kinases in a spatiotemporal cellular context. In this review, we will summarize the knowledge on the role of kinases in PH and focus on druggable targets for which certain criteria are met: (a) deregulation of the kinase in PH; (b) small-molecule inhibitors are available (e.g. from the oncology field); (c) preclinical studies have shown their efficacy in PH models; and (d) when available, therapeutic exploitation in human PH has been initiated. Along this line, clinical considerations such as personalized medicine approaches to predict therapy response and adverse side events such as cardiotoxicity together with their clinical management are discussed. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.1/issuetoc.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
31-53Subventions
Organisme : Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
ID : 268555672 -SFB 1213, PROJECT A08
Informations de copyright
© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Abe, K., Shimokawa, H., Morikawa, K., Uwatoku, T., Oi, K., Matsumoto, Y., … Takeshit, A. (2004). Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circulation Research, 94(3), 385-393. https://doi.org/10.1161/01.RES.0000111804.34509.94
Abe, K., Tawara, S., Oi, K., Hizume, T., Uwatoku, T., Fukumoto, Y., … Shimokawa, H. (2006). Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. Journal of Cardiovascular Pharmacology, 48(6), 280-285. https://doi.org/10.1097/01.fjc.0000248244.64430.4a
Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., … CGTP Collaborators (2017). The concise guide to pharmacology 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174(Suppl 1), S17-S129. https://doi.org/10.1111/bph.13878
Alexander, S. P., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., … CGTP Collaborators (2017a). The concise guide to pharmacology 2017/18: Catalytic receptors. British Journal of Pharmacology, 174(Suppl 1), S225-S271. https://doi.org/10.1111/bph.13876
Alexander, S. P., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., … CGTP Collaborators (2017b). The concise guide to pharmacology 2017/18: Enzymes. British Journal of Pharmacology, 174(Suppl 1), S272-S359. https://doi.org/10.1111/bph.13877
Aspeslagh, S., Shailubhai, K., Bahleda, R., Gazzah, A., Varga, A., Hollebecque, A., … Soria, J. C. (2017). Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 79(6), 1257-1265. https://doi.org/10.1007/s00280-017-3303-z
Bahleda, R., Grilley-Olson, J. E., Govindan, R., Barlesi, F., Greillier, L., Perol, M., … Soria, J. C. (2017). Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 116(12), 1505-1512. https://doi.org/10.1038/bjc.2017.92
Bai, Y., Yang, J., Liu, J., Ning, H., & Zhang, R. (2019). Right atrial function for the prediction of prognosis in connective tissue disease-associated pulmonary arterial hypertension: A study with two-dimensional speckle tracking. The International Journal of Cardiovascular Imaging, 35(9), 1637-1649. https://doi.org/10.1007/s10554-019-01613-w
Basciani, S., Brama, M., Mariani, S., De Luca, G., Arizzi, M., Vesci, L., … Gnessi, L. (2005). Imatinib mesylate inhibits Leydig cell tumor growth: Evidence for in vitro and in vivo activity. Cancer Research, 65(5), 1897-1903. https://doi.org/10.1158/0008-5472.CAN-04-2181
Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A. E., & McGoon, M. D. (2012). An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest, 142(2), 448-456. https://doi.org/10.1378/chest.11-1460
Beppu, K., Jaboine, J., Merchant, M. S., Mackall, C. L., & Thiele, C. J. (2004). Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. Journal of the National Cancer Institute, 96(1), 46-55. https://doi.org/10.1093/jnci/djh004
Berendzen, K., Theriaque, D. W., Shuster, J., & Stacpoole, P. W. (2006). Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion, 6(3), 126-135. https://doi.org/10.1016/j.mito.2006.04.001
Bonnet, S., Provencher, S., Guignabert, C., Perros, F., Boucherat, O., Schermuly, R. T., … Humbert, M. (2017). Translating research into improved patient care in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 195(5), 583-595. https://doi.org/10.1164/rccm.201607-1515PP
Boucherat, O., Provencher, S., & Bonnet, S. (2018). Therapeutic value of ASK1 inhibition in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 197(3), 284-286.
Bracarda, S., Negrier, S., Casper, J., Porta, C., Schmidinger, M., Larkin, J., … Escudier, B. (2017). How clinical practice is changing the rules: The sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 17(3), 227-233. https://doi.org/10.1080/14737140.2017.1276830
Budas, G. R., Boehm, M., Kojonazarov, B., Viswanathan, G., Tian, X., Veeroju, S., … Weissmann, N. (2018). ASK1 inhibition halts disease progression in preclinical models of pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 197(3), 373-385.
Cantoni, S., Cavalli, S., Pastore, F., Accetta, A., Pala, D., Vaccaro, F., … Facchinetti, F. (2019). Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension. European Journal of Pharmacology, 850, 126-134.
Chaar, M., Kamta, J., & Ait-Oudhia, S. (2018). Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. OncoTargets and Therapy, 11, 6227-6237.
Chen, J., Tang, H., Sysol, J. R., Moreno-Vinasco, L., Shioura, K. M., Chen, T., … Sammani, S. (2014). The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 190(9), 1032-1043.
Cheng, Y., Yu, M., Xu, J., He, M., Wang, H., Kong, H., & Xie, W. (2018). Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. BMC Pulmonary Medicine, 18(1), 130.
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., … George, S. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (London, England), 370(9604), 2011-2019.
Church, A. C., Martin, D. H., Wadsworth, R., Bryson, G., Fisher, A. J., Welsh, D. J., & Peacock, A. J. (2015). The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-α: A potential novel anti-inflammatory strategy in pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology, 309(4), L333-L347.
Ciuclan, L., Hussey, M. J., Burton, V., Good, R., Duggan, N., Beach, S., … Bonneau, O. (2013). Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. American Journal of Respiratory and Critical Care Medicine, 187(1), 78-89.
Crnkovic, S., Egemnazarov, B., Damico, R., Marsh, L. M., Nagy, B. M., Douschan, P., … Ghanim, B. (2018). Disconnect between fibrotic response and right ventricular dysfunction. American Journal of Respiratory and Critical Care Medicine.
Csiszar, A., Labinskyy, N., Olson, S., Pinto, J. T., Gupte, S., Wu, J. M., … De Cabo, R. (2009). Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension, 54(3), 668-675.
Dahal, B. K., Cornitescu, T., Tretyn, A., Pullamsetti, S. S., Kosanovic, D., Dumitrascu, R., … Seeger, W. (2010). Role of epidermal growth factor inhibition in experimental pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 181(2), 158-167.
Dahal, B. K., Kosanovic, D., Pamarthi, P. K., Sydykov, A., Lai, Y. J., Kast, R., … Grimminger, F. (2010). Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. The European Respiratory Journal, 36(4), 808-818.
de Raaf, M. A., Herrmann, F. E., Schalij, I., de Man, F. S., Vonk-Noordegraaf, A., Guignabert, C., … Bogaard, H. J. (2016). Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats. American journal of physiology. Heart and Circulatory Physiology, 311(3), H604-H612.
Dong, J., & Chen, H. (2018). Cardiotoxicity of anticancer therapeutics. Frontiers in Cardiovascular Medicine, 5, 9. https://doi.org/10.3389/fcvm.2018.00009
Durairaj, C., Ruiz-Garcia, A., Gauthier, E. R., Huang, X., Lu, D. R., Hoffman, J. T., … Zheng, J. (2018). Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs, 29(3), 271-280.
Egemnazarov, B., Crnkovic, S., Nagy, B. M., Olschewski, H., & Kwapiszewska, G. (2018). Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions. Matrix Biology: Journal of the International Society for Matrix Biology, 68-69, 507-521.
Eisen, T., Loembe, A. B., Shparyk, Y., MacLeod, N., Jones, R. J., Mazurkiewicz, M., … Bondarenko, I. (2015). A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 113(8), 1140-1147.
Evans, J. D., Girerd, B., Montani, D., Wang, X. J., Galie, N., Austin, E. D., … Jing, Z. C. (2016). BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis. The Lancet. Respiratory Medicine, 4(2), 129-137.
Ferdinandy, P., Baczko, I., Bencsik, P., Giricz, Z., Gorbe, A., Pacher, P., … Schulz, R. (2019). Definition of hidden drug cardiotoxicity: Paradigm change in cardiac safety testing and its clinical implications. European Heart Journal, 40(22), 1771-1777.
Frost, A. E., Barst, R. J., Hoeper, M. M., Chang, H. J., Frantz, R. P., Fukumoto, Y., … Morrell, N. W. (2015). Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation, 34(11), 1366-1375.
Fukumoto, Y., Matoba, T., Ito, A., Tanaka, H., Kishi, T., Hayashidani, S., … Shimokawa, H. (2005). Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart, 91(3), 391-392.
Fukumoto, Y., Yamada, N., Matsubara, H., Mizoguchi, M., Uchino, K., Yao, A., … Adachi, T. (2013). Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circulation Journal: Official Journal of the Japanese Circulation Society, 77(10), 2619-2625.
Furuya, Y., Satoh, T., & Kuwana, M. (2010). Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. International Journal of Rheumatology, 2010, 720305.
Gairhe, S., Joshi, S. R., Bastola, M. M., McLendon, J. M., Oka, M., Fagan, K. A., & McMurtry, I. F. (2016). Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension. Pulmonary Circulation, 6(3), 369-380.
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2019). Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription, 10(2), 118-136.
Genovese, M. C., Cohen, S. B., Wofsy, D., Weinblatt, M. E., Firestein, G. S., Brahn, E., … Tong, S. E. (2011). A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. The Journal of Rheumatology, 38(5), 846-854.
Gessler, T. (2018). Inhalation of repurposed drugs to treat pulmonary hypertension. Advanced Drug Delivery Reviews, 133, 34-44.
Ghofrani, H. A., Morrell, N. W., Hoeper, M. M., Olschewski, H., Peacock, A. J., Barst, R. J., … Pascoe, S. (2010). Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. American Journal of Respiratory and Critical Care Medicine, 182(9), 1171-1177.
Ghofrani, H. A., Seeger, W., & Grimminger, F. (2005). Imatinib for the treatment of pulmonary arterial hypertension. The New England Journal of Medicine, 353(13), 1412-1413.
Gomberg-Maitland, M., Maitland, M. L., Barst, R. J., Sugeng, L., Coslet, S., Perrino, T. J., … Ratain, M. J. (2010). A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clinical Pharmacology and Therapeutics, 87(3), 303-310.
Goncharova, E. A. (2013). mTOR and vascular remodeling in lung diseases: Current challenges and therapeutic prospects. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 27(5), 1796-1807.
Gore, B., Izikki, M., Mercier, O., Dewachter, L., Fadel, E., Humbert, M., … Eddahibi, S. (2014). Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension. PLoS ONE, 9(6), e100310.
Gosal, K., Dunlop, K., Dhaliwal, R., Ivanovska, J., Kantores, C., Desjardins, J. F., … Jankov, R. P. (2015). Rho kinase mediates right ventricular systolic dysfunction in rats with chronic neonatal pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 52(6), 717-727.
Guignabert, C., Phan, C., Seferian, A., Huertas, A., Tu, L., Thuillet, R., … Chaumais, M. C. (2016). Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. The Journal of Clinical Investigation, 126(9), 3207-3218.
Guignabert, C., Tu, L., Le Hiress, M., Ricard, N., Sattler, C., Seferian, A., … Montani, D. (2013). Pathogenesis of pulmonary arterial hypertension: Lessons from cancer. European Respiratory Review: An Official Journal of the European Respiratory Society, 22(130), 543-551.
Halliday, S. J., & Hemnes, A. R. (2017). Identifying “super responders” in pulmonary arterial hypertension. Pulmonary Circulation, 7(2), 300-311.
Haque, S., & Morris, J. C. (2017). Transforming growth factor-β: A therapeutic target for cancer. Human Vaccines & Immunotherapeutics, 13(8), 1741-1750.
Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., … Bryant, C. (2018). The IUPHAR/BPS guide to pharmacology in 2018: Updates and expansion to encompass the new guide to immunopharmacology. Nucleic Acids Research, 46(D1), D1091-D1106.
Harston, R. K., McKillop, J. C., Moschella, P. C., Van Laer, A., Quinones, L. S., Baicu, C. F., … Kuppuswamy, D. (2011). Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. American Journal of Physiology. Heart and Circulatory Physiology, 300(5), H1696-H1706.
Hasinoff, B. B., Patel, D., & Wu, X. (2017). The myocyte-damaging effects of the BCR-ABL1-targeted tyrosine kinase inhibitors increase with potency and decrease with specificity. Cardiovascular Toxicology, 17(3), 297-306.
Hoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galie, N., … Ghofrani, H. A. (2013). Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation, 127(10), 1128-1138.
Houssaini, A., & Adnot, S. (2017). mTOR: A key to both pulmonary vessel remodeling and right ventricular function in pulmonary arterial hypertension? American Journal of Respiratory Cell and Molecular Biology, 57(5), 509-511.
Irsan, I., Akisue, T., Hara, H., Fujimoto, T., Imabori, M., Doita, M., … Kurosaka, M. (2007). Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Research, 27(1A), 423-429.
Ishikura, K., Yamada, N., Ito, M., Ota, S., Nakamura, M., Isaka, N., & Nakano, T. (2006). Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circulation Journal: Official Journal of the Japanese Circulation Society, 70(2), 174-178.
Iyinikkel, J., & Murray, F. (2018). GPCRs in pulmonary arterial hypertension: Tipping the balance. British Journal of Pharmacology, 175(15), 3063-3079.
Jiang, R., Ai, Z. S., Jiang, X., Yuan, P., Liu, D., Zhao, Q. H., … Jing, Z. C. (2015). Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 38(8), 539-544.
Jiang, X., Wang, Y. F., Zhao, Q. H., Jiang, R., Wu, Y., Peng, F. H., … Jing, Z. C. (2014). Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: A randomized, controlled, crossover study. International Journal of Cardiology, 177(1), 61-65.
Kan, M., Shumyatcher, M., & Himes, B. E. (2017). Using omics approaches to understand pulmonary diseases. Respiratory Research, 18(1), 149.
Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., … Rosenzweig, A. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12(8), 908-916.
King, H., Aleksic, T., Haluska, P., & Macaulay, V. M. (2014). Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treatment Reviews, 40(9), 1096-1105.
Kojonazarov, B., Myrzaakhmatova, A., Sooronbaev, T., Ishizaki, T., & Aldashev, A. (2012). Effects of fasudil in patients with high-altitude pulmonary hypertension. The European Respiratory Journal, 39(2), 496-498.
Kojonazarov, B., Novoyatleva, T., Boehm, M., Happe, C., Sibinska, Z., Tian, X., … Evans, S. M. (2017). p38 MAPK inhibition improves heart function in pressure-loaded right ventricular hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 57(5), 603-614.
Kojonazarov, B., Sydykov, A., Pullamsetti, S. S., Luitel, H., Dahal, B. K., Kosanovic, D., … Phillips, P. (2013). Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. International Journal of Cardiology, 167(6), 2630-2637.
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., … Costabel, U. (2017). Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review: An Official Journal of the European Respiratory Society, 26(146).
Lenihan, D. J., & Kowey, P. R. (2013). Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. The Oncologist, 18(8), 900-908.
Leong, Z. P., Okida, A., Higuchi, M., Yamano, Y., & Hikasa, Y. (2018). Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats. Vascular Pharmacology, 100, 41-50.
Li, B., Yan, J., Shen, Y., Liu, Y., & Ma, Z. (2014). Dichloroacetate prevents but not reverses the formation of neointimal lesions in a rat model of severe pulmonary arterial hypertension. Molecular Medicine Reports, 10(4), 2144-2152.
Lien, E. C., Lyssiotis, C. A., & Cantley, L. C. (2016). Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches Sur le Cancer, 207, 39-72.
Lin, S. F., Lin, J. D., Hsueh, C., Chou, T. C., & Wong, R. J. (2018). Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Endocrine-Related Cancer, 25(10), 853-864.
Loibl, S., Turner, N. C., Ro, J., Cristofanilli, M., Iwata, H., Im, S. A., … Verma, S. (2017). Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. The Oncologist, 22(9), 1028-1038.
Lomas, D. A., Lipson, D. A., Miller, B. E., Willits, L., Keene, O., Barnacle, H., & Tal-Singer, R. (2012). An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. Journal of Clinical Pharmacology, 52(3), 416-424.
Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., … Subramanian, G. M. (2017). The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology.
Low, A. T., Howard, L., Harrison, C., & Tulloh, R. M. (2015). Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica, 100(6), e244-e245.
Lu, Z., Wu, C. Y., Jiang, Y. P., Ballou, L. M., Clausen, C., Cohen, I. S., & Cohen, I. S. (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Science Translational Medicine, 4(131), 131ra150.
Maarman, G., Lecour, S., Butrous, G., Thienemann, F., & Sliwa, K. (2013). A comprehensive review: The evolution of animal models in pulmonary hypertension research; are we there yet? Pulmonary Circulation, 3(4), 739-756.
MacNee, W., Allan, R. J., Jones, I., De Salvo, M. C., & Tan, L. F. (2013). Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: A randomised clinical trial. Thorax, 68(8), 738-745.
MacRitchie, N., Volpert, G., Al Washih, M., Watson, D. G., Futerman, A. H., Kennedy, S., … Pyne, N. J. (2016). Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cellular Signalling, 28(8), 946-955.
McMurtry, M. S., Bonnet, S., Wu, X., Dyck, J. R., Haromy, A., Hashimoto, K., & Michelakis, E. D. (2004). Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circulation Research, 95(8), 830-840.
Michelakis, E. D., Gurtu, V., Webster, L., Barnes, G., Watson, G., Howard, L., … O'Regan, D. P. (2017). Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 9(413).
Michelakis, E. D., McMurtry, M. S., Wu, X. C., Dyck, J. R., Moudgil, R., Hopkins, T. A., … Archer, S. L. (2002). Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation, 105(2), 244-250.
Michelakis, E. D., Webster, L., & Mackey, J. R. (2008). Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. British Journal of Cancer, 99(7), 989-994.
Milara, J., Ballester, B., Morell, A., Ortiz, J. L., Escriva, J., Fernandez, E., … Morcillo, E. (2018). JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: An experimental study. Thorax, 73(6), 519-529.
Mita, M. M., Mita, A. C., Moseley, J. L., Poon, J., Small, K. A., Jou, Y. M., … Sankhala, K. K. (2017). Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. British Journal of Cancer, 117(9), 1258-1268.
Mohri, M., Shimokawa, H., Hirakawa, Y., Masumoto, A., & Takeshita, A. (2003). Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. Journal of the American College of Cardiology, 41(1), 15-19.
Moran, N. (2011). p38 kinase inhibitor approved for idiopathic pulmonary fibrosis. Nature Biotechnology, 29(4), 301.
Nako, H., Kataoka, K., Koibuchi, N., Dong, Y. F., Toyama, K., Yamamoto, E., … Kim-Mitsuyama, S. (2012). Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: The critical role of ASK1 and VEGF. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 35(2), 194-200.
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., … Lederer, D. J. (2017). Effect of pirfenidone on mortality: Pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. The Lancet. Respiratory Medicine, 5(1), 33-41.
Nishimura, T., Faul, J. L., Berry, G. J., Veve, I., Pearl, R. G., & Kao, P. N. (2001). 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. American Journal of Respiratory and Critical Care Medicine, 163(2), 498-502.
O'Donoghue, M. L., Glaser, R., Cavender, M. A., Aylward, P. E., Bonaca, M. P., Budaj, A., … Hamm, C. (2016). Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: A randomized clinical trial. Jama, 315(15), 1591-1599.
Olgar, Y., Celen, M. C., Yamasan, B. E., Ozturk, N., Turan, B., & Ozdemir, S. (2017). Rho-kinase inhibition reverses impaired Ca2+ handling and associated left ventricular dysfunction in pressure overload-induced cardiac hypertrophy. Cell Calcium, 67, 81-90.
Oltmanns, U., Kahn, N., Palmowski, K., Trager, A., Wenz, H., Heussel, C. P., … Warth, A. (2014). Pirfenidone in idiopathic pulmonary fibrosis: Real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration; International Review of Thoracic Diseases, 88(3), 199-207.
Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009). Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica (Stockholm, Sweden), 48(7), 964-970.
Paddenberg, R., Stieger, P., von Lilien, A. L., Faulhammer, P., Goldenberg, A., Tillmanns, H. H., … Braun-Dullaeus, R. C. (2007). Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respiratory Research, 8, 15.
Paulin, R., Meloche, J., & Bonnet, S. (2012). STAT3 signaling in pulmonary arterial hypertension. Jak-Stat, 1(4), 223-233.
Pena, A., Kobir, A., Goncharov, D., Goda, A., Kudryashova, T. V., Ray, A., … Gorcsan, J. III (2017). Pharmacological inhibition of mTOR kinase reverses right ventricle remodeling and improves right ventricle structure and function in rats. American Journal of Respiratory Cell and Molecular Biology, 57(5), 615-625.
Piao, L., Fang, Y. H., Cadete, V. J., Wietholt, C., Urboniene, D., Toth, P. T., … Lopaschuk, G. D. (2010). The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle. Journal of Molecular Medicine (Berlin, Germany), 88(1), 47-60.
Piao, L., Fang, Y. H., Parikh, K. S., Ryan, J. J., D'Souza, K. M., Theccanat, T., … Akhter, S. A. (2012). GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: Therapeutic implications in pulmonary hypertension. Circulation, 126(24), 2859-2869.
Poble, P. B., Phan, C., Quatremare, T., Bordenave, J., Thuillet, R., Cumont, A., … Ghigna, M. R. (2019). Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 33(3), 3670-3679.
Prada, L. F., Gavilanes, F., & Souza, R. (2015). Incidence of spontaneous subdural hematoma in incident cases of pulmonary arterial hypertension: A registry of cases occurring over a five-year period. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 41(1), 101-102.
Pullamsetti, S. S., Berghausen, E. M., Dabral, S., Tretyn, A., Butrous, E., Savai, R., … Weissmann, N. (2012). Role of Src tyrosine kinases in experimental pulmonary hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(6), 1354-1365.
Pullamsetti, S. S., Savai, R., Seeger, W., & Goncharova, E. A. (2017). Translational advances in the field of pulmonary hypertension. From cancer biology to new pulmonary arterial hypertension therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. American journal of respiratory and critical care medicine, 195(4), 425-437.
Pyne, N. J., & Pyne, S. (2017). Sphingosine kinase 1: A potential therapeutic target in pulmonary arterial hypertension? Trends in Molecular Medicine, 23(9), 786-798.
Querejeta Roca, G., Campbell, P., Claggett, B., Solomon, S. D., & Shah, A. M. (2015). Right atrial function in pulmonary arterial hypertension. Circulation. Cardiovascular imaging, 8(11), e003521.
Querejeta Roca, G., Campbell, P., Claggett, B., Vazir, A., Quinn, D., Solomon, S. D., & Shah, A. M. (2015). Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. European Journal of Heart Failure, 17(1), 63-73.
Rahmani, H., Shahriary, A., Sheikhi, M. A., Ebadi, A., & Davoodzadeh, H. (2017). Applications of cardiotoxicity in breast cancer: A meta-analysis. Panminerva Medica, 59(1), 90-96.
Rainbolt, T. K., Saunders, J. M., & Wiseman, R. L. (2014). Stress-responsive regulation of mitochondria through the ER unfolded protein response. Trends in Endocrinology and Metabolism: TEM, 25(10), 528-537.
Reck, M., Horn, L., Novello, S., Barlesi, F., Albert, I., Juhasz, E., … Chung, J. (2019). Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 14(4), 701-711.
Richter, M. J., Ewert, J., Grimminger, F., Ghofrani, H. A., Kojonazarov, B., Petrovic, A., … Gall, H. (2018). Nintedanib in severe pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 198(6), 808-810.
Rodon, J., Carducci, M. A., Sepulveda-Sanchez, J. M., Azaro, A., Calvo, E., Seoane, J., … Pillay, N. S. (2015). First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21(3), 553-560.
Rol, N., de Raaf, M. A., Sun, X. Q., Kuiper, V. P., da Silva Goncalves Bos, D., Happe, C., … Guignabert, C. (2019). Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension. Cardiovascular Research, 115(2), 432-439.
Rol, N., Kurakula, K. B., Happe, C., Bogaard, H. J., & Goumans, M. J. (2018). TGF-β and BMPR2 signaling in PAH: Two black sheep in one family. International Journal of Molecular Sciences, 19(9).
Rosenkranz, S., Feldman, J., McLaughlin, V., Rischard, F., White, J., Ebrahimi, R., … Lange, T. (2017). The ARROW study: A phase 2, prospective, randomized, double-blind, placebo-controlled study of selonsertib in subjects with pulmonary arterial hypertension. European Respiratory Journal, 50(suppl 61), OA1983.
Roskoski, R. Jr. (2019). Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 144, 19-50.
Savale, L., Guignabert, C., Weatherald, J., & Humbert, M. (2018). Precision medicine and personalising therapy in pulmonary hypertension: Seeing the light from the dawn of a new era. European Respiratory Review: An Official Journal of the European Respiratory Society, 27(148).
Schermuly, R. T., Dony, E., Ghofrani, H. A., Pullamsetti, S., Savai, R., Roth, M., … Grimminger, F. (2005). Reversal of experimental pulmonary hypertension by PDGF inhibition. The Journal of Clinical Investigation, 115(10), 2811-2821.
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011). Mechanisms of disease: Pulmonary arterial hypertension. Nature reviews. Cardiology, 8(8), 443-455.
Schmidinger, M., Larkin, J., & Ravaud, A. (2012). Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 4(5), 253-265.
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., … Schmidinger, H. (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(32), 5204-5212.
Seyfarth, H. J., Hammerschmidt, S., Halank, M., Neuhaus, P., & Wirtz, H. R. (2013). Everolimus in patients with severe pulmonary hypertension: A safety and efficacy pilot trial. Pulmonary Circulation, 3(3), 632-638.
Shah, A. M., Campbell, P., Rocha, G. Q., Peacock, A., Barst, R. J., Quinn, D., & Solomon, S. D. (2015). Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. European Heart Journal, 36(10), 623-632.
Shi, L., Kojonazarov, B., Elgheznawy, A., Popp, R., Dahal, B. K., Bohm, M., … Katus, H. A. (2016). miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: A novel therapeutic approach. Cardiovascular Research, 111(3), 184-193.
Shi, W., Zhai, C., Feng, W., Wang, J., Zhu, Y., Li, S., … Liu, P. (2018). Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation. Life Sciences, 210, 140-149.
Sitbon, O., Gomberg-Maitland, M., Granton, J., Lewis, M. I., Mathai, S. C., Rainisio, M., … Rubin, L. J. (2019). Clinical trial design and new therapies for pulmonary arterial hypertension. The European Respiratory Journal, 53(1).
Southan, C., Sharman, J. L., Faccenda, E., Pawson, A. J., Harding, S. D., & Davies, J. A. (2018). Challenges of connecting chemistry to pharmacology: Perspectives from curating the IUPHAR/BPS guide to pharmacology. ACS Omega, 3(7), 8408-8420.
Speich, R., Ulrich, S., Domenighetti, G., Huber, L. C., Fischler, M., Treder, U., & Breitenstein, A. (2015). Efficacy and safety of long-term imatinib therapy for pulmonary arterial hypertension. Respiration; International Review of Thoracic Diseases, 89(6), 515-524.
Spiekerkoetter, E., Sung, Y. K., Sudheendra, D., Scott, V., Del Rosario, P., Bill, M., … Zamanian, R. T. (2017). Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. The European Respiratory Journal, 50(3).
Spiekerkoetter, E., Tian, X., Cai, J., Hopper, R. K., Sudheendra, D., Li, C. G., … Haghighat, L. (2013). FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. The Journal of Clinical Investigation, 123(8), 3600-3613.
Tabarroki, A., Lindner, D. J., Visconte, V., Zhang, L., Rogers, H. J., Parker, Y., … Mountantonakis, S. E. (2014). Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia, 28(7), 1486-1493.
Tefferi, A., & Pardanani, A. (2011). Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clinic Proceedings, 86(12), 1188-1191.
Tello, K., Dalmer, A., Axmann, J., Vanderpool, R., Ghofrani, H. A., Naeije, R., … Gall, H. (2019). Reserve of right ventricular-arterial coupling in the setting of chronic overload. Circulation. Heart failure, 12(1), e005512.
ten Freyhaus, H., Dagnell, M., Leuchs, M., Vantler, M., Berghausen, E. M., Caglayan, E., … Kappert, K. (2011). Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. American Journal of Respiratory and Critical Care Medicine, 183(8), 1092-1102.
Thomas, M., Docx, C., Holmes, A. M., Beach, S., Duggan, N., England, K., … Walker, C. (2009). Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. The American Journal of Pathology, 174(2), 380-389.
Tiede, S. L., Gall, H., Dorr, O., dos Santos, G. M., Troidl, C., Liebetrau, C., … Grimminger, F. (2015). New potential diagnostic biomarkers for pulmonary hypertension. The European Respiratory Journal, 46(5), 1390-1396.
Totzeck, M., Mincu, R. I., Mrotzek, S., Schadendorf, D., & Rassaf, T. (2018). Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. European Journal of Preventive Cardiology, 25(5), 482-494.
Touyz, R. M., & Herrmann, J. (2018). Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precision Oncology, 2, 13.
Tuder, R. M., Archer, S. L., Dorfmuller, P., Erzurum, S. C., Guignabert, C., Michelakis, E., … Morrell, N. W. (2013). Relevant issues in the pathology and pathobiology of pulmonary hypertension. Journal of the American College of Cardiology, 62(25 Suppl), D4-D12.
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G. J., Heymans, M. W., Bogaard, H. J., … Vonk-Noordegraaf, A. (2011). Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. Journal of the American College of Cardiology, 58(24), 2511-2519.
Verstovsek, S. (2009). Therapeutic potential of JAK2 inhibitors. Hematology. American Society of Hematology. Education Program: 636-642.
Viswanathan, G., Mamazhakypov, A., Schermuly, R. T., & Rajagopal, S. (2018). The role of G protein-coupled receptors in the right ventricle in pulmonary hypertension. Frontiers in Cardiovascular Medicine, 5, 179.
Vitko, S., Margreiter, R., Weimar, W., Dantal, J., Kuypers, D., Winkler, M., … Li, Y. (2005). Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 5(10), 2521-2530.
Walker, J. E., & Margolin, S. B. (2001). Pirfenidone for chronic progressive multiple sclerosis. Multiple Sclerosis, 7(5), 305-312.
Wang, Y., Wu, Y., Chen, J., Zhao, S., & Li, H. (2013). Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology, 126(1), 1-11.
Weatherald, J., Chaumais, M. C., & Montani, D. (2017). Pulmonary arterial hypertension induced by tyrosine kinase inhibitors. Current Opinion in Pulmonary Medicine, 23(5), 392-397.
Weatherald, J., Chaumais, M. C., Savale, L., Jais, X., Seferian, A., Canuet, M., … Sitbon, O. (2017). Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: A population-based study. The European Respiratory Journal, 50(1).
Weiss, A., Neubauer, M. C., Yerabolu, D., Kojonazarov, B., Schlueter, B. C., Neubert, L., … Pullamsetti, S. S. (2019). Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 10(1), 2204.
Woodcock, C. C., & Chan, S. Y. (2019). The search for disease-modifying therapies in pulmonary hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 1074248419829172.
Yang, D. L., Zhang, H. G., Xu, Y. L., Gao, Y. H., Yang, X. J., Hao, X. Q., & Li, X. H. (2010). Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clinical and Experimental Pharmacology & Physiology, 37(2), 150-155.
Yu, X., Zhao, X., Zhang, J., Li, Y., Sheng, P., Ma, C., … Qiao, H. (2019). Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension. European Journal of Pharmacology, 850, 97-108.
Zaiman, A. L., Podowski, M., Medicherla, S., Gordy, K., Xu, F., Zhen, L., … Chakravarty, S. (2008). Role of the TGF-β/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 177(8), 896-905.
Zhang, Y., & Wu, S. (2017). Effects of fasudil on pulmonary hypertension in clinical practice. Pulmonary Pharmacology & Therapeutics, 46, 54-63.